This association was independent of the presence of TNBC and age suggesting that assessment of TOP1 may substantially improve prediction of BRCA1/2 mutations, in particular in breast carcinomas with hormone-receptor positive or HER2 positive breast cancer diagnosed in women aged ≥ 45 years. This evidence concerns the gene TOP1 and breast carcinoma.